Anti-cancer Drug Maker Zionpharma Closes Series A+ at USD 20 Mn
Zionpharma, as an anti-cancer drug developer in the small molecular area, announced the close of Series A+ fundraising of up to USD 20 million. The bankroll will help promote the Phase I clinical trial of the core pipeline, complete the investigational new drug (IND) and candidate screening at the pre-clinical stage.
The investment was led by Sherpa VC and Qiming Ventures, participated by Mefung Capital. This fundraising is the third time within the last two years since the foundation in 2018. The management team characterizes the differentiation and high tech-threshold of its pipelines as the core competency.